Wharton S, Calanna S, Davies M, et al. - Among adults with overweight or obesity, it was found that gastrointestinal (GI) adverse events (AEs) were more common and were typically mild-to-moderate and transient when treatment with semaglutide 2.4 mg was received, compared with placebo.

• Data were pooled from the semaglutide Treatment Effect in People With Obesity (STEP) 1-3 trials for participants randomly assigned to 68 weeks of semaglutide 2.4 mg (n = 2117) or placebo (n = 1262).

• Experts assessed GI tolerability with semaglutide 2.4 mg maintenance and discontinuation after dose escalation utilizing STEP 4 data among 803 participants tolerating 20 weeks of semaglutide run-in.

• Semaglutide 2.4 mg more commonly led to GI AEs vs placebo, with most frequently nausea (43.9% vs 16.1% of participants), diarrhea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%) and constipation (24.2% vs 11.1%).

• The majority of semaglutide-induced GI AEs were non-serious (99.5% of AEs), mild-to-moderate (98.1%), transient and happened most frequently during/shortly following dose escalation.

• Weight loss caused by semaglutide was largely independent of GI AEs.

• In STEP 4, good tolerability of semaglutide 2.4 mg maintenance was evident.